Indication
In combination with chemotherapy, followed by maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma (FL).

Medicine details

Medicine name:
obinutuzumab (Gazyvaro)
SMC ID:
SMC2015
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Advice due date:
10 September 2018
SMC meeting date:
07 August 2018
Patient group submission deadline:
04 June 2018